Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patientsâ lives using the Companyâs platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has open Phase 1/2 clinical trials in hemophilia A and hemophilia B, lysosomal storage disorders MPS I and MPS II, as well as beta thalassemia. Sangamo has an exclusive, global collaboration and license agreement with Kite, a Gilead company, for engineered cell therapies for oncology, with Pfizer Inc. for gene therapy programs for Hemophilia A, with Bioverativ for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntingtonâs disease. In addition, it has established strategic partnerships with companies in non-therapeutic applications of its technology, including MilliporeSigma and Dow AgroSciences.
Source
